Form 4: IGM Biosciences Executive Lisa Decker Reports Acquisition of Stock and Stock Options

Lisa Decker, Chief Business Officer of IGM Biosciences, reports the acquisition of restricted stock units and stock options.

Summary

• Lisa Lynn Decker, Chief Business Officer of IGM Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On March 12, 2024, Decker acquired 28,750 restricted stock units (RSUs) at $0, representing a contingent right to receive one share of IGM Biosciences' common stock per RSU.
• One-sixteenth of the RSUs will vest on June 12, 2024, and every three months thereafter, contingent upon continued service.
• On the same date, Decker also acquired options to purchase 57,500 shares of common stock at an exercise price of $9.95, expiring on March 12, 2034.
• One forty-eighth of the shares subject to the option will vest on April 12, 2024, and each month thereafter, contingent upon continued service.
• Following these transactions, Decker directly owns 64,382 shares of common stock and options for 57,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock and options by an executive is generally seen as a sign of confidence, but it's a routine transaction.

Positives

• The acquisition of RSUs and stock options by a key executive could be interpreted as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the Reporting Person remaining a service provider, suggesting an incentive for continued employment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for executives in the biotechnology industry.
• The vesting schedules described are fairly standard, designed to incentivize long-term commitment.
• Comparing the size of the grant to those of executives at comparable companies (e.g., Amgen, Regeneron, Biogen) would provide further context on its significance.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they indicate insider confidence.
• The vesting schedules incentivize the executive to remain with the company, which benefits employees and other stakeholders.

Key Dates